c‑MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo

Jia,Yitao; Dai,Guangyao; Wang,Jinxi; Gao,Xing; Zhao,Zhaolong; Duan,Zhihui; Gu,Bin; Yang,Weiguang; Wu,Jianhua; Ju,Yingchao; Wang,Mingxia; Li,Zhongxin

doi:10.3892/ol.2016.4303

c‑MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo

Authors:
- Yitao Jia
- Guangyao Dai
- Jinxi Wang
- Xing Gao
- Zhaolong Zhao
- Zhihui Duan
- Bin Gu
- Weiguang Yang
- Jianhua Wu
- Yingchao Ju
- Mingxia Wang
- Zhongxin Li
View Affiliations

Affiliations: Third Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050011, P.R. China, Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China, Fourth Department of General Surgery, The First Hospital of Handan, Handan, Hebei 056002, P.R. China, Second Department of Abdominal Surgery, The First Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054001, P.R. China, Experimental Animal Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: March 3, 2016 https://doi.org/10.3892/ol.2016.4303
Pages: 2879-2885

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of hepatocyte growth factor receptor (c‑Met) inhibition on the viability of colon cancer cells and xenografts exposed to irradiation using short hairpin (sh)RNA or the c‑MET inhibitor PHA665752. The underlying mechanisms were also investigated. Human colorectal adenocarcinoma HT‑29 cells were infected with a lentivirus expressing shRNAs against c‑Met and were irradiated at 0, 2, 4, 6 and 8 Gy. The viability of the cells was assessed by alamarBlue® assays. Mice bearing human colon carcinoma SW620 xenografts were randomly selected to receive 2.5% dimethyl sulfoxide (DMSO), 25 mg/kg PHA665752 intraperitoneally once every 2 days for 3 weeks, irradiation at 10 Gy, or 25 mg/kg PHA665752 intraperitoneally once every 2 days for 3 weeks followed 24 h later by irradiation at 10 Gy. The mean tumor volume (MTV) was measured. The apoptotic rate of cells was detected by terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling (TUNEL) assays, and double stranded break marker antibody γ‑H2AX and hypoxia inducible factor (HIF)‑1α expression was examined by immunohistochemistry. alamarBlue assays revealed that c‑Met downregulation by shRNA markedly accentuated the irradiation‑induced reduction in the viability of HT‑29 cells compared with HT‑29 cells irradiated at the same doses (P<0.05). A combination of irradiation and PHA665752 caused an additional reduction in the MTV (382.8±42.4 mm3; P<0.01 vs. irradiation and PHA665752, 998.0±180.6 and 844.8±190.0 mm3, respectively). TUNEL assays revealed that irradiation and PHA665752 alone caused significant apoptosis of the SW620 cells in the tumor xenografts (P<0.01 vs. DMSO). The apoptotic index in the tumor xenografts of mice treated with a combination of irradiation and PHA665752 was significantly increased compared with mice treated with either agent alone (P<0.01). The combination of irradiation and PHA665752 was also associated with a marked increase in γ‑H2AX levels and a significant decrease in HIF‑1α expression in the xenografts (P<0.01). In conclusion, c‑Met inhibition sensitizes colorectal cancer cells to irradiation by enhancing the formation of DNA double strand breaks and possibly alleviating tumor hypoxia.

View Figures

View References

1	Robbins AS, Siegel RL and Jemal A: Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 30:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC: EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
3	Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
4	Dhadda AS, Dickinson P, Zaitoun AM, Gandhi N and Bessell EM: Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. Eur J Cancer. 47:1138–1145. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hu T, Yao Y, Yu S, Guo H, Han L, Wang W, Tian T, Hao Y, Liu Z, Nan K and Wang S: Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer. J Biomed Res. 27:283–290. 2013. View Article : Google Scholar : PubMed/NCBI
6	Scarpino S, d'Alena Cancellario F, Di Napoli A, Pasquini A, Marzullo A and Ruco LP: Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol. 202:352–358. 2004. View Article : Google Scholar : PubMed/NCBI
7	De Wever O, Nguyen QD, Van Hoorde L, Bracke M, Bruyneel E, Gespach C and Mareel M: Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 18:1016–1018. 2004.PubMed/NCBI
8	Park MK, Kim DK and Lee HJ: Adenoviral mediated hepatocyte growth factor gene attenuates hyperglycemia and beta cell destruction in overt diabetic mice. Exp Mol Med. 35:494–500. 2003. View Article : Google Scholar : PubMed/NCBI
9	Comoglio PM and Trusolino L: Invasive growth: From development to metastasis. J Clin Invest. 109:857–862. 2002. View Article : Google Scholar : PubMed/NCBI
10	Stellrecht CM and Gandhi V: MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 280:1–14. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB and Weiser MR: Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248:219–228. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M: Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res. 60:6148–6159. 2000.PubMed/NCBI
13	Du Z, Qin R, Wei C, Wang M, Shi C, Tian R and Peng C: Pancreatic cancer cells resistant to chemoradiotherapy rich in “stem-cell-like” tumor cells. Dig Dis Sci. 56:741–750. 2011. View Article : Google Scholar : PubMed/NCBI
14	Suárez-Causado A, Caballero-Díaz D, Bertrán E, Roncero C, Addante A, García-Álvaro M, Fernández M, Herrera B, Porras A, Fabregat I and Sánchez A: HGF/c-Met signaling promotes liver progenitor cell migration and invasion by an epithelial-mesenchymal transition-independent, phosphatidyl inositol-3 kinase-dependent pathway in an in vitro model. Biochim Biophys Acta. 1853:2453–2463. 2015. View Article : Google Scholar : PubMed/NCBI
15	De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM and Boccaccio C: Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 103:645–661. 2011. View Article : Google Scholar : PubMed/NCBI
16	Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ and Camphausen K: Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med. 15:1999–2006. 2011. View Article : Google Scholar : PubMed/NCBI
17	Sun W, Song L, Ai T, Zhang Y, Gao Y and Cui J: Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J Biomed Res. 27:220–230. 2013. View Article : Google Scholar : PubMed/NCBI
18	National Research Council of the National Academies: Guide for the care and use of laboratory animals (8th). The National Academies Press. Washington, D.C., USA: 199–200. 2011.
19	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
20	Singh H, Daci K, Petersen LA, Collins C, Petersen NJ, Shethia A and El-Serag HB: Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. Am J Gastroenterol. 104:2543–2554. 2009. View Article : Google Scholar : PubMed/NCBI
21	Bekaii-Saab T and Wu C: Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol. 91:9–34. 2014. View Article : Google Scholar : PubMed/NCBI
22	Teicher BA: Antiangiogenic agents and targets: A perspective. Biochem Pharmacol. 81:6–12. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M: Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 32:1527–1531. 2012.PubMed/NCBI
24	Hong TS, Wo JY and Kwak EL: Targeted therapies with chemoradiation in esophageal cancer: Development and future directions. Semin Radiat Oncol. 23:31–37. 2013. View Article : Google Scholar : PubMed/NCBI
25	Akervall J, Nandalur S, Zhang J, Qian CN, Goldstein N, Gyllerup P, Gardinger Y, Alm J, Lorenc K, Nilsson K, et al: A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 50:570–581. 2014. View Article : Google Scholar : PubMed/NCBI
26	Medová M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S and Zimmer Y: MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest. Genes Cancer. 1:1053–1062. 2010. View Article : Google Scholar : PubMed/NCBI
27	Medová M, Aebersold DM and Zimmer Y: MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer. 130:728–734. 2012. View Article : Google Scholar : PubMed/NCBI
28	Zhuang HQ, Bo QF, Yuan ZY, Wang J, Zhao LJ and Wang P: The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction. Onco Targets Ther. 6:603–608. 2013. View Article : Google Scholar : PubMed/NCBI
29	Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D and Stea B: The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 4:692009. View Article : Google Scholar : PubMed/NCBI
30	Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A and Burgess TL: AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 13:6735–6742. 2007. View Article : Google Scholar : PubMed/NCBI
31	Fan S, Wang JA, Yuan RQ, Rockwell S, Andres J, Zlatapolskiy A, Goldberg ID and Rosen EM: Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene. 17:131–141. 1998. View Article : Google Scholar : PubMed/NCBI
32	Meyn RE, Munshi A, Haymach JV, Milas L and Ang KK: Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol. 92:316–322. 2009. View Article : Google Scholar : PubMed/NCBI
33	Abdollahi A and Folkman J: Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 13:16–28. 2010. View Article : Google Scholar : PubMed/NCBI
34	Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G and Salgia R: A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67:3529–3534. 2007. View Article : Google Scholar : PubMed/NCBI
35	Citrin D, Ménard C and Camphausen K: Combining radiotherapy and angiogenesis inhibitors: Clinical trial design. Int J Radiat Oncol Biol Phys. 64:15–25. 2006. View Article : Google Scholar : PubMed/NCBI